| Vyzulta (U.S.N.L.M.) | |
|---|---|
| Dosing | 1 drop daily in the evening |
| Chem Specs | latanoprostene bunod 0.024% |
| Quantities | 5ml |
| Cost | 260.49 |
| Class | nitric oxide-donating prostaglandin F2α analog |
| Action | Increases trabecular meshwork and uveoscleral aqueous outflow. |
| Slightly better IOP control than latanoprost. (7 to 9 mmHg IOP reduction from average baseline of 26.7 mmHg in one study). |
|
| Usage | Indicated for reduction of IOP in open angle glaucoma or ocular hypertension. |
| Side Effects | Increased pigmentation of the iris and periorbital tissue (eyelid). Possible cystoid macular edema in pseudophakes and aphakes. |
| Contraindications | Hypersensitivity to Vyzulta or any other ingredient in the product. Avoid with active intraocular inflammation. |
| Pediatric use | Avoid in patients aged 16 years and younger due potential safety concerns related to increased pigmentation following long-term chronic use. |
| Pregnancy | No available human data for the use of VYZULTA during pregnancy. Causes miscarriage, abortion, and fetal harm in rabbits. |
| 0.02% BAK preserved. May be stored at room temperature for 2 months. | |
| Nitric oxide (a free radical) increases trabecular outflow. |